Preview

Экспериментальная и клиническая гастроэнтерология

Расширенный поиск

Метаболический синдром и кардиоваскулярная патология: фокус на неалкогольную жировую болезнь печени

https://doi.org/10.31146/1682-8658-ecg-183-11-62-69

Полный текст:

Аннотация

В последние годы неалкогольная жировая болезнь печени (НАЖБП) ассоциирована с метаболическим синдромом (МС) и рассматривается в качестве одного из его компонентов. Смертность пациентов с НАЖБП обусловлена не столько прогрессированием поражения печени, сколько кардиоваскулярными осложнениями. В настоящем обзоре обобщены современные данные о возможных патофизиологических механизмах, связывающих НАЖБП и сердечно-сосудистые заболевания. Анализируются клинические последствия влияния НАЖБП на сердце и сосуды: атеросклероз, ремоделирование миокарда, нарушения ритма и проводимости, хроническая сердечная недостаточность.

Об авторах

С. П. Саликова
ФГБВОУ ВО «Военно-медицинская академия им. С. М. Кирова» МО РФ
Россия

Саликова Светлана Петровна, д. м. н., доцент, доцент 2 кафедры (терапии усовершенствования врачей)

194044, Санкт-Петербург, улица Академика Лебедева, дом 6



Е. С. Иванюк
ФГБВОУ ВО «Военно-медицинская академия им. С. М. Кирова» МО РФ
Россия

Иванюк Елена Сергеевна, к. м. н., преподаватель 2 кафедры (терапии усовершенствования врачей)

194044, Санкт-Петербург, улица Академика Лебедева, дом 6



Список литературы

1. Townsend N, Nichols M, Scarborough P, et al. Cardiovascular disease in Europe–epidemiological update 2015. Eur Heart J 2015; 36:2696–705.

2. Mensah GA, Roth GA, Sampson UK, et al. Mortality from cardiovascular diseases in sub-Saharan Africa, 1990–2013: a systematic analysis of data from the Global Burden of Disease Study 2013. Cardiovasc J Afr 2015; 26 Suppl 1: S6–10.

3. Leong DP, Joseph PG, McKee M, et al. Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. Circ Res. 2017;121(6):695–710.

4. Оганов Р.Г., Симаненков В. И., Бакулин И. Г., Бакулина Н. В., и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019;18(1):5–66. https://doi.org/10.15829/1728–88002019–1–5–66.

5. Ansarimoghaddam A, Adineh HA, Zareban I, Iranpour S, HosseinZadeh A, Kh F. Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies. Diabetes Metab Syndr. 2018;12(2):195–201.

6. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12.

7. Yang S, Kwak S, Lee JH, Kang S, Lee SP. Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population. PLoS One. 2019;14(11): e0224626.

8. Caballeria L.l., Auladell A. M., Toran P. et al. Prevalence and factors associated with the presence of non alcoholic fatty liver disease in an apparently healthy adult population in primary care units. BMC Gastroenterology. 2007. Vol. 7, 41 P.

9. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629–636.

10. Mozaffary A, Bozorgmanesh M, Sheikholeslami F, et al. Added value of different metabolic syndrome defi nitions for predicting cardiovascular disease and mortality events among elderly population: Tehran Lipid and Glucose Study. Eur J Clin Nutr 2014;68:853–8.

11. Ju SY, Lee JY, Kim DH. Association of metabolic syndrome and its components with all-cause and cardiovascular mortality in the elderly: A meta-analysis of prospective cohort studies. Medicine (Baltimore). 2017;96(45): e8491.

12. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.

13. Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol. 2019;70(3):531–544.

14. Ekstedt, M.; Hagström, H.; Nasr, P.; Fredrikson, M.; Stål, P.; Kechagias, S.; Hultcrantz, R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015, 61, 1547–1554.

15. Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309.

16. Anstee QM, Day CP. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Semin Liver Dis. 2015;35(3):270–290.

17. Kahali B, Liu YL, Daly AK, Day CP, Anstee QM, Speliotes EK. TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?. Gastroenterology. 2015;148(4):679–684.

18. Francque SM, van der Graaff D, Kwanten WJ. Nonalcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425–443.

19. Buckley AJ, Thomas EL, Lessan N, Trovato FM, Trovato GM, Taylor-Robinson SD. Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints. Diabetes Res Clin Pract. 2018;144:144–152.

20. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048.

21. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–1560.

22. Kolovou GD, Watts GF, Mikhailidis DP, et al. Postprandial Hypertriglyceridaemia Revisited in the Era of NonFasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. Curr Vasc Pharmacol. 2019;17(5):515–537.

23. Pappas C, Kandaraki EA, Tsirona S, Kountouras D, Kassi G, Diamanti-Kandarakis E. Postprandial dysmetabolism: Too early or too late?. Hormones (Athens). 2016;15(3):321–344.

24. Alkhouri N, Tamimi TA, Yerian L, Lopez R, Zein NN, Feldstein AE. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci. 2010;55(9):2644–2650.

25. Tana C, Ballestri S, Ricci F, et al. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019;16(17):3104.

26. Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1062–1079.

27. Shi J, Fan J, Su Q, Yang Z. Cytokines and Abnormal Glucose and Lipid Metabolism. Front Endocrinol (Lausanne). 2019;10:703.

28. Pereira ENGDS, Silvares RR, Flores EEI, et al. Hepatic microvascular dysfunction and increased advanced glycation end products are components of non-alcoholic fatty liver disease. PLoS One. 2017;12(6): e0179654.

29. Jaruvongvanich V, Chenbhanich J, Sanguankeo A, Rattanawong P, Wijarnpreecha K, Upala S. Increased arterial stiff ness in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(9): e28-e35.

30. Ste_en, H.; Demir, M.; Lang, S.; Schulte, S.; Töx, U. High rate of undetected arterial hypertension in patients with non-alcoholic steatohepatitis (Nash): PP.34.356. J. Hypertens. 2010, 28, e557.

31. Sanduzzi Zamparelli M, Compare D, Coccoli P, et al. The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. Int J Mol Sci. 2016;17(8):1225.

32. Ismaiel A, Dumitraşcu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne). 2019;6:202.

33. Zhang Y, Xu J, Wang X, Ren X, Liu Y. Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. BMC Genomics. 2019;20(1):862.

34. Vlasov AA, Salikova SP, Grinevich VB, Bystrova OV, Osipov GA, Meshkova ME. Gut Microbiota and Systemic Inflammation in Patients With Chronic Heart Failure. Kardiologiia. 2020;60(5):859.

35. Lim S, Taskinen MR, Borén J. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obes Rev. 2019;20(4):599–611.

36. Xanthopoulos A, Starling RC, Kitai T, Triposkiadis F. Heart Failure and Liver Disease: Cardiohepatic Interactions. JACC Heart Fail. 2019;7(2):87–97.

37. Chen YM, Liu Y, Zhou RF, et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep. 2016;6:19076.

38. Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313–324.

39. Dongiovanni P, Romeo S, Valenti L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int. 2015;2015:460190.

40. Dai G, Liu P, Li X, Zhou X, He S. Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis. Medicine (Baltimore). 2019;98(7): e14324.

41. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2018;68(2):268–279.

42. Wang C, Gong J, Wu H. Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease. Biomed Rep. 2017;7(2):95–104.

43. Jain V, Kumar A, Ahmad N, et al. Genetic polymorphisms associated with obesity and non-alcoholic fatty liver disease in Asian Indian adolescents. J Pediatr Endocrinol Metab. 2019;32(7):749–758.

44. Villasante Fricke AC, Iacobellis G. Epicardial Adipose Tissue: Clinical Biomarker of Cardio-Metabolic Risk. Int J Mol Sci. 2019;20(23):5989.

45. Caprio S, Perry R, Kursawe R. Adolescent Obesity and Insulin Resistance: Roles of Ectopic Fat Accumulation and Adipose Inf lammation. Gastroenterology. 2017;152(7):1638–1646.

46. Zafar U, Khaliq S, Ahmad HU, Manzoor S, Lone KP. Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links. Hormones (Athens). 2018;17(3):299–313.

47. Liu B, Li Y, Li Y, et al. Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis. Hepatol Int. 2019;13(6):757–765.

48. Meng X, Wang W, Zhang K, et al. Epicardial adipose tissue volume is associated with non-alcoholic fatty liver disease and cardiovascular risk factors in the general population. Ther Clin Risk Manag. 2018;14:1499–1506.

49. Hallsworth K, Hollingsworth KG, Thoma C, et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol. 2013;58(4):757–762.

50. VanWagner LB, Wilcox JE, Colangelo LA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology. 2015;62(3):773–783.

51. Lee YH, Kim KJ, Yoo ME, et al. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J Hepatol. 2018;68(4):764–772.

52. Petta S, Argano C, Colomba D, et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol. 2015;62(4):928–933.

53. Wannamethee SG, Whincup PH, Shaper AG, Lennon L, Sattar N. Γ-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol. 2012;32(3):830–835.

54. Yilmaz Y, Kurt R, Yonal O, et al. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis. 2010;211(1):182–186.

55. De Sensi F, Costantino S, Limbruno U, Paneni F. Atrial fibrillation in the cardiometabolic patient. Minerva Med. 2019;110(2):157–167.

56. Georgakopoulos C, Vlachopoulos C, Lazaros G, Tousoulis D. Biomarkers of Atrial Fibrillation in Metabolic Syndrome. Curr Med Chem. 2019;26(5):898–908.

57. Wijarnpreecha K, Boonpheng B, Thongprayoon C, Jaruvongvanich V, Ungprasert P. The association between non-alcoholic fatty liver disease and atrial fibrillation: A meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(5):525–532.

58. Targher G, Valbusa F, Bonapace S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One. 2013;8(2): e57183.

59. Mantovani A, Dauriz M, Sandri D, et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. Liver Int. 2019;39(4):758–769.

60. Zhang Y, Li P, Miao M, et al. Nonalcoholic Fatty Liver Disease Is Associated with Increased Atrial Fibrillation Risk in an Elderly Chinese Population: A Cross-Sectional Study. Biomed Res Int. 2018;2018:5628749.

61. Markus MR, Meffert PJ, Baumeister SE, et al. Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population: The Study of Health in Pomerania (SHIP). Atherosclerosis. 2016;245:123–131.

62. Mantovani A. NAFLD and risk of cardiac arrhythmias: Is hyperuricemia a neglected pathogenic mechanism?. Dig Liver Dis. 2018;50(5):518–520.

63. Mantovani A, Rigamonti A, Bonapace S, et al. Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring. Diabetes Care. 2016;39(8):1416–1423.

64. Targher G, Valbusa F, Bonapace S, et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014;24(6):663–669.

65. Hung CS, Tseng PH, Tu CH, et al. Nonalcoholic Fatty Liver Disease Is Associated With QT Prolongation in the General Population. J Am Heart Assoc. 2015;4(7): e001820.

66. Mantovani A, Rigolon R, Pichiri I, et al. Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. PLoS One. 2017;12(10): e0185459.

67. Ozveren O, Dogdu O, Sengul C, et al. Deterioration of heart rate recovery index in patients with non-alcoholic fatty liver disease (NAFLD). Med Sci Monit. 2014;20:1539–1543.

68. Cai J, Zhang S, Huang W. Association between nonalcoholic fatty liver disease and carotid atherosclerosis: a meta-analysis. Int J Clin Exp Med. 2015;8(5):7673–7678.

69. Chung GE, Choi SY, Kim D, et al. Nonalcoholic fatty liver disease as a risk factor of arterial stiff ness measured by the cardioankle vascular index. Medicine (Baltimore). 2015;94(12): e654.

70. Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis. 2013;230(2):258–267.

71. Kapuria D, Takyar VK, Etzion O, Surana P, O’Keefe JH, Koh C. Association of Hepatic Steatosis With Subclinical Atherosclerosis: Systematic Review and Meta-Analysis. Hepatol Commun. 2018;2(8):873–883. Published 2018 Jul 6.

72. Chang Y, Ryu S, Sung KC, et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. Gut. 2019;68(9):1667–1675.

73. Kim MK, Ahn CW, Nam JS, Kang S, Park JS, Kim KR. Association between nonalcoholic fatty liver disease and coronary artery calcification in postmenopausal women. Menopause. 2015;22(12):1323–1327.

74. Wong VW, Wong GL, Yip GW, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut. 2011;60(12):17211727.

75. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Nonalcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J. 2012;33(10):1190–1200.

76. Kunutsor SK, Apekey TA, Khan H. Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis. 2014;236(1):7–17.

77. Koenig G, Seneff S. Gamma-Glutamyltransferase: A Predictive Biomarker of Cellular Antioxidant Inadequacy and Disease Risk. Dis Markers. 2015;2015:818570.


Для цитирования:


Саликова С.П., Иванюк Е.С. Метаболический синдром и кардиоваскулярная патология: фокус на неалкогольную жировую болезнь печени. Экспериментальная и клиническая гастроэнтерология. 2020;183(11):62-69. https://doi.org/10.31146/1682-8658-ecg-183-11-62-69

For citation:


Salikova S.P., Ivanyuk E.S. Metabolic syndrome and cardiovascular pathology: focus on non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2020;183(11):62-69. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-183-11-62-69

Просмотров: 99


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)